SynthesisBMC infectious diseases2025
Prevalence of genital and anorectal chlamydia trachomatis in Kenya by risk groups: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Novel Multiplex Near-Point-of-Care PCR Assay for Detecting Sexually Transmitted Infections Among PrEP Users in Western Kenya: Protocol for a Cross-Sectional Pilot Study With an Epidemiological Assessment.JMIR research protocols · 2026Article
- Prevalence and Tetracycline Susceptibility ofMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology of Chlamydia trachomatis (CT) in Kenya is not well understood. We conducted a systematic review and meta-analysis of CT prevalence using PubMed, Embase, and Kenyan databases (Jan 2000-June 2024). Included studies had laboratory-confirmed CT and were peer-reviewed. Populations were categorized by sex/gender and STI vulnerability. A random-effects model was used to account for heterogeneity. Of 198 records, 51 studies (32,559 participants) were included. CT prevalence was reported for 18 studies on males, 36 on females, and four on the general population. Pooled prevalence was 5.8% (95% CI 4.6-7.4) with high heterogeneity. The highest prevalence was among general population females > 25 years (14.8%), while at risk males > 25 had the lowest (0.1%). Studies spanned 13 regions, with Nairobi, Kisumu, and Mombasa most represented. CT prevalence in Kenya aligns with WHO estimates for Africa. High prevalence among general population women > 25 challenges traditional STI risk assumptions. Importantly, the association between HIV and CT was not uniform across populations, suggesting that relying solely on HIV-focused platforms may overlook groups with a substantial CT burden. Addressing diagnostic gaps, urban-rural disparities, and links with HIV care is critical.Trial registration CRD42024567235.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.